Arcutis Biotherapeutics, Inc.
ARQT
Rang în acțiuni
#4008
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to... Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
Preț acțiune
$32.29
Ultima sincronizare: 2026-10-19
Capitalizare de piață
$4.06B
Schimbare (1 zi)
12.02%
Schimbare (1 an)
54.62%
Țară
US
Tranzacționează Arcutis Biotherapeutics, Inc. (ARQT)
Categorie
Healthcare
Raport P/S pentru Arcutis Biotherapeutics, Inc. (ARQT)
Raport P/S la data de October 2026 TTM: 7.15
Conform celor mai recente rapoarte financiare și prețului acțiunilor Arcutis Biotherapeutics, Inc., raportul P/S actual (TTM) este 7.15. La sfârșitul anului 2023, compania avea un P/S de 3.76.
Istoricul raportului P/S pentru Arcutis Biotherapeutics, Inc. din 2017 până în 2026
Raport P/S la sfârșitul fiecărui an
| An | Raport P/S | Schimbă |
|---|---|---|
| 2026 (TTM) | 7.15 | -16.55% |
| 2024 | 8.57 | 128.27% |
| 2023 | 3.76 | -98.30% |
| 2022 | 220.96 | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
Raport P/S pentru companii similare sau competitoare
| Companie | Raport P/S | Diferență raport P/S | Țara |
|---|---|---|---|
| 10.02 | 40.14% |
US
|
|
| 40.55 | 467.01% |
US
|
|
| 3.96 | -44.61% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | 41.87% |
NL
|
